Cytokinetics Inc Discusses Results from FORTITUDE-ALS Transcript
Good morning. My name is Robert Blum, and it's my pleasure to welcome you to the Cytokinetics webcast to discuss the results of the FORTITUDE-ALS trial that were announced here yesterday at the American Academy of Neurology Annual Meeting in Philadelphia. This meeting is convening here in Philadelphia but is also being webcast, and we welcome those people who were dialed into the webcast.
Today, we're going to elaborate on some very important data that were presented yesterday at the AAN relating to the development of reldesemtiv for the potential treatment of ALS.
I'll be making and others will be making some forward-looking statements. We will refer you to our SEC filings with regard to caveats to those statements. We do not undertake any obligations to update those statements.
As you know and to set some context, Cytokinetics is a pioneer in developing a new pharmacology relating to modulators of the contractility of muscle, different types of muscle. Today, we're going to be in particular talking
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |